Market News / Story
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
GlobeNewswire ·
GlobeNewswire reports: Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (the “ Company ”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“ AUD ”), today announced…
Related stories
Japan's Takaichi Rules Out Need for Reflationary Measures, Affirms BOJ IndependenceRead story summary
Japans Takaichi Rules Out Need for Reflationary Measures, Affirms BOJ Independence Japans Takaichi Seeks Market Trust Through Open and Transparent Communication
VIEW SOURCE